Abstract:
:Monoclonal B-cell lymphocytosis (MBL) is a recently defined medical condition that displays biological similarities to chronic lymphocytic leukemia (CLL), the most common subtype of adult leukemia in the Western world. MBL may be diagnosed in individuals with a normal lymphocyte count via a screening assay (screening MBL) or through the clinical evaluation of lymphocytosis (clinical MBL). Clinical MBL, which resembles CLL with a good prognosis, has attracted considerable interest because of its clinical and biological implications. The biological profile of clinical MBL appears indistinguishable from that of CLL for a large variety of markers. Differential diagnosis between clinical MBL and CLL is mainly based on peripheral blood B-cell counts. The 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria changed the definition of CLL to a B-cell count ≥ 5.0 × 10(9)/L to eliminate overlap between CLL and MBL. However, this cut-off is arbitrary, and recent studies suggest that a B-cell count of 10.0-11.0 × 10(9)/L may represent the threshold that best predicts time to first treatment. After a diagnosis of clinical MBL, patients should be educated about appropriate monitoring and follow-up keeping in mind that, with time and counseling, most patients will understand that clinical MBL and CLL represent a continuum.
journal_name
Leuk Lymphomajournal_title
Leukemia & lymphomaauthors
Molica S,Mauro FR,Molica M,Del Giudice I,Foà Rdoi
10.3109/10428194.2012.666542subject
Has Abstractpub_date
2012-09-01 00:00:00pages
1660-5issue
9eissn
1042-8194issn
1029-2403journal_volume
53pub_type
杂志文章,评审abstract::Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diag...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2014.963080
更新日期:2015-06-01 00:00:00
abstract::The percentage of blasts in the bone marrow aspirates at day 7 or 14 of induction therapy in pediatric ALL patients is an indicator of rapid early response and an independent prognostic factor for long term outcome. Discrepancies between the percentages of blasts in bone marrow aspirates compared to biopsies have been...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190310001625863
更新日期:2004-04-01 00:00:00
abstract::Speed of response to therapy predicts outcome in childhood lymphoblastic leukaemia. This observation has been made studying both blood and bone marrow in children on widely differing treatment regimens from the 1970s to the present day. It appears to be independent of other classical prognostic factors such as age and...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199809057609
更新日期:1998-11-01 00:00:00
abstract::The aim of this study was to evaluate the influence of the most common genetic variants in methylenetetrahydrofolate reductase (MTHFR), thiopurine methyltransferase (TPMT) and glutathione-S-transferases (GSTs) on the outcome of acute lymphoblastic leukemia (ALL) treatment in Argentinean children. Two hundred and eight...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2014.951844
更新日期:2015-05-01 00:00:00
abstract::A two-year-old boy presented with pancytopenia. Bone marrow examination revealed an aplastic marrow with prominent immature plasma cell proliferation, which mimicked plasma cell leukemia. Immunohistochemistry, however, revealed a polyclonal population consistent with a reactive process, excluding plasma cell neoplasia...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199909145722
更新日期:1999-09-01 00:00:00
abstract::Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%)...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2016.1251592
更新日期:2017-06-01 00:00:00
abstract::Interleukin-6 (IL-6) has been shown to increase platelet counts in several animal models and to enhance megakaryocytopoiesis in vitro. In order to investigate the possible relationship between IL-6 and thrombocytosis, serum IL-6 levels in patients with platelet counts > or = 6 x 10(5)/microliters were measured using a...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199209054910
更新日期:1992-10-01 00:00:00
abstract::Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428194.2018.1457147
更新日期:2018-12-01 00:00:00
abstract::Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohis...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2017.1334121
更新日期:2018-02-01 00:00:00
abstract::FB2 is a novel Abl/Src dual tyrosine kinase inhibitor which is designed to overcome imatinib resistance. Besides imatinib-sensitive cell lines (K562), FB2 significantly inhibited the growth of imatinib-resistant cell lines of different resistance mechanisms (K562/G5.0 and K562/G01), and decreased the expression of aut...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190802709438
更新日期:2009-03-01 00:00:00
abstract::Expression of T, sialosyl-T and disialosyl-T antigens on normal blood and bone marrow cells as well as transformed cells was examined using specific monoclonal antibodies and multidimensional flow cytometry. Both anti-sialosyl-T (QSH1) and anti-disialosyl-T (QSH2) monoclonal antibodies aggregated erythrocytes. The ant...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199709039027
更新日期:1997-05-01 00:00:00
abstract::Actinomycin D, a transcriptional inhibitor, was found to inhibit platelet potentiation by thrombopoietin (TPO), suggesting that TPO stimulation of platelets involves mitochondrial transcription. We sought to determine a possible role for leukemia-associated signal transducers and activators of transcription (STAT) pro...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/1042819022386716
更新日期:2002-07-01 00:00:00
abstract::The expression of c-kit receptor (c-kit R; CD117) and CD34 was examined in acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML) in blastic transformation (BT), and myelofibrosis (MF) in myeloid BT. In myeloid leukemia including AML, CML-myeloid BT and MF-myeloid BT, both c-kit R ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199509049769
更新日期:1995-01-01 00:00:00
abstract::Although the association of bone marrow fibrosis with plasma cell dyscrasias has already been described in several reports, the close relationship between these entities still remains unclear. In this report we describe a patient with clinical and pathologic findings which initially suggested a diagnosis of myelofibro...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199309148567
更新日期:1993-07-01 00:00:00
abstract::Akt (protein kinase B) is a serine/threonine kinase involved in the regulation of cell survival signals. Akt is expressed in T- and B-lymphocytes and is activated in response to cytokine and antigen-receptor stimulation. Three isoforms of Akt have been identified, Akt-1, -2 and -3, but the expression pattern and speci...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190500159944
更新日期:2005-12-01 00:00:00
abstract::We review results of intensive chemotherapy (IC) obtained in myelodysplastic syndromes (MDS). Overall, the complete remission (CR) rates and median CR duration obtained with IC are low in MDS, especially when compared to results obtained in de novo AML treated with the same chemotherapy regimens; very few MDS patients...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199209049816
更新日期:1992-09-01 00:00:00
abstract::CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituxima...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,多中心研究
doi:10.1080/10428194.2019.1643463
更新日期:2019-12-01 00:00:00
abstract::Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with an association with inflammation and viral infections. We hypothesize that environmental factors may be involved in the pathogenesis of DLBCL. In this study, we compared gene expression profiles of lymph node tissues from patients with DLBCL from tw...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2012.738365
更新日期:2013-05-01 00:00:00
abstract::There is little evidence about whether additional risk stratification for adult patients with acute lymphoblastic leukemia age 65 and older is warranted. Using the Surveillance, Epidemiology, and End Results data linked to Medicare claims, we examined the effects of age, comorbid conditions, and mobility limitations o...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2018.1555329
更新日期:2019-08-01 00:00:00
abstract::One of the possible causes of treatment failure in acute leukemia is the emergence of multidrug resistance caused by P-glycoprotein (P-gp) overexpression. We compared a flow cytometric assay using JC-1 with a technique using rhodamine 123 (rho123) to evaluate the P-gp function in acute leukemia. Samples from 50 acute ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190412331272767
更新日期:2004-11-01 00:00:00
abstract::The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders. Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway. A cell line hom...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190701607576
更新日期:2007-11-01 00:00:00
abstract::Large granular lymphocyte disorder (LGLD) is a lymphoproliferative disease, characterized by moderate lymphocytosis with an excess of large granular lymphocytes, neutropenia, anemia, and a variable, but mostly chronic clinical course. We describe two patients with LGLD. One patient presented with symptomatic corticost...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199109064883
更新日期:1991-01-01 00:00:00
abstract::Extranodal adult T-cell leukemia/lymphoma (ATLL) of the head and neck is a rare disease. We studied the clinicopathological features of nine patients with ATLL involving extranodal head and neck sites and conducted a literature review. Six patients presented with extranodal mass of the head and neck, whereas three had...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190802702383
更新日期:2009-02-01 00:00:00
abstract::There is an abundance of data dealing with recirculation of T cells in the rats, but relatively little is known about the traffic of B cells. The adhesion molecules expressed on the surface membrane are of great significance for recirculation of lymphocytes. However, very little is known about the expression of variou...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/1042819021000033006
更新日期:2002-11-01 00:00:00
abstract::Peripheral T-cell lymphomas are characterized by a poor clinical outcome. We retrospectively analyzed 208 adults treated in our institution between 2000 and 2011. Median age at diagnosis was 55 years. Fifty-one percent had B symptoms and 51% serum elevated lactate dehydrogenase (LDH) levels. Eastern Cooperative Oncolo...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2013.776680
更新日期:2013-11-01 00:00:00
abstract::Continuous Wilms' tumor gene (WT1) expression is a typical feature of leukemic blasts in AML, ALL, and blast crisis CML patients. It is easily detectable by a variety of RT-PCR protocols, which differ mainly in their sensitivity. The nuclear WT1 protein can be found in blasts of approximately 50-60% of acute leukemia ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190009148849
更新日期:2000-01-01 00:00:00
abstract::Monitoring of t(14;18) in blood or bone marrow in follicular lymphoma (FL) remains controversial. We attempted to monitor t(14;18) in lymph nodes by ultrasound-guided fine needle aspirations (UG-FNA). First, we confirmed t(14;18) in 27/31 UG-FNAs of lymph nodes with fluorescent in situ hybridisation (FISH) and/or poly...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190902927005
更新日期:2009-07-01 00:00:00
abstract::B lymphocytes from the peripheral blood of patients with chronic lymphocytic leukaemia (CLL) were analysed for the nuclear presence and DNA binding of a panel of transcription factors which are involved in the gene control of lymphoid cells. The following transcription factors were studied: the Octamer factors Oct-1 a...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199609054868
更新日期:1996-11-01 00:00:00
abstract::PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-daily PTK787/ZK222584 at a target dose of 1250 mg. Eighteen patien...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2013.784969
更新日期:2013-12-01 00:00:00
abstract::Multiple myeloma represents a B cell malignancy characterized by a monoclonal proliferation of plasma cells. A striking feature of the disease is the tendency of the malignant plasma cells to affect mainly the bone marrow environment and to invade the peripheral blood only in the terminal stage. The growth of myeloma ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199309145751
更新日期:1993-04-01 00:00:00